Subscribe to GlobalData Explorer to access actionable intelligence spanning 22 industries, 200+ economies and 700k+ companies on a single platform

Number of ongoing Clinical Trials (for drugs) involving Simplexvirus (HSV) Infections by Phase

  • There are currently 22 ongoing clinical trials involving Simplexvirus (HSV) Infections

  • Of the 22 trials,6 trials are in Phase III

  • Furthermore, 5 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Simplexvirus (HSV) Infections by Phase

Published: October 2021
Source: GlobalData

The global pharmaceutical industry is steadily developing new drugs for Simplexvirus (HSV), an Infectious Disease. The largest number of ongoing clinical trials for Simplexvirus (HSV) is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Simplexvirus (HSV)-related drug trials.

Maruho Co Ltd: The leading ongoing Simplexvirus (HSV) related clinical trial sponsor

Maruho Co Ltd is the top sponsor for Simplexvirus (HSV)-related ongoing clinical trials.

Labolife Belgium Sprl, Heidelberg Immunotherapeutics Gmbh, Jupiter Wellness Inc, and University of Liverpool are among other notable clinical trial sponsors involved in Simplexvirus (HSV). A clinical trial sponsor can be a Company, Government, Individual, or Institution. 

Marketed Drugs involving Simplexvirus (HSV)  

Valacyclovir hydrochloride (Valtrex, Zelitrex, Valherpes, Virval, Zimivir, Rapivir), Dimepranol acedoben, and Vidarabine (Arasena A) are among the key marketed drugs involving Simplexvirus (HSV). 

Valacyclovir hydrochloride (Valtrex, Zelitrex, Valherpes, Virval, Zimivir, Rapivir) is an antiviral agent. It functions via DNA Polymerase (EC 2.7.7.7) Inhibitor mechanism of action. Valacyclovir hydrochloride is formulated as film coated tablets, tablets, coated tablets and granules for oral route of administration. Valacyclovir hydrochloride was first approved in 1995 and is marketed Globally in the US, Japan, the UK, China, Germany and France by several prominent pharma giants including GlaxoSmithKline LLC. 

Dimepranol acedoben also known as Inosine acedoben dimepranol or  Inosine pranobex (Groprinosin) is a combinatinon of inosine, acetamidobenzoic acid and dimethylaminoisopropanol acts as an antiviral agent. It functions via T Cell Differentiation Antigen CD6 (T12 or TP120 or CD6) Activator mechanism of action. Dimepranol acedoben is formulated as tablets for oral route of administration. Inosine pranobex is indicated for the treatment of immunodeficiency states caused by viral infections in patients with normal and compromised immune systems, including disease caused by the virus herpes simplex (type I and type II, genital herpes and cold sores other localization); subacute sclerosing panencephalitis. Dimepranol acedoben was first approved in 2008 and is marketed solely in Russia by Gedeon Richter – RUS.



Explore, track and compare industries, economies and companies in a single platform through GlobalData Explorer.​

Single License $700 per month (billed Annually)
Multiple Licenses Connect with a GlobalData representative to discover our offers for multiple licenses​
  • 700K+Companies
  • 22Industries
  • 15K+Reports
  • 200+Countries & Regions
Still looking?

Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.

Explorer

Access more premium companies when you subscribe to Explorer